This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT
Transcript : Esperion Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell MT
Top Premarket Gainers MT
Transcript : Esperion Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $137.7M, vs. Street Est of $83.9M MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01 MT
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol DJ
Sector Update: Health Care Stocks Steady Premarket Monday MT
Transcript : Esperion Therapeutics, Inc. - Special Call
Top Premarket Gainers MT
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use CI
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet MT
Esperion Says FDA Approves New Labels for Nexletol and Nexlizet DJ
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update MT
Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications DJ
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination CI
Transcript : Esperion Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
North American Morning Briefing : Stock Futures -2- DJ
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q4 Revenue $32.3M, vs. Street Est of $28.7M MT
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data MT
Chart Esperion Therapeutics, Inc.
More charts
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.17 USD
Average target price
7.414 USD
Spread / Average Target
+241.67%
Consensus
  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. News Esperion Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Steady Premarket Monday